



Study of the Role of Efflux Pumps in Amikacin-Resistant *Acinetobacter* Isolates from Teaching Hospitals of Mashhad, Iran

Maryam Abbasi Shaye,¹ Mohammad Reza Sharifmoghadam,^{1*} Masoumeh Bahreini,¹ Kiarash Ghazvini,² Asghar Mafinezhad,³ and Ghazale Amiri¹

¹Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran

²Department of Microbiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

³Microbiology Laboratory, Shahid Kamyab Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

*Corresponding author: Mohammad Reza Sharifmoghadam, Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran. Tel: +98-51338805524, E-mail: m_sharifmoghadam@yahoo.com

Received 2017 July 11; Revised 2018 January 23; Accepted 2018 March 01.

Abstract

Background: The development of multidrug-resistant *Acinetobacter* species has created serious problems in nosocomial infections. Understanding the underlying resistance mechanisms and their significance in conferring resistance to different antibiotics is the first step to develop strategies for fighting or reversing the current resistance.

Objectives: The aim of this study was to investigate the role of efflux pumps in decreasing susceptibility to amikacin in *Acinetobacter* clinical isolates.

Methods: Forty-six clinical *Acinetobacter* isolates were collected from 2 teaching hospitals of Mashhad, Iran. Susceptibility testing was conducted by the disc diffusion method. Amikacin minimum inhibitory concentration (MIC) for resistant *Acinetobacter* isolates was determined according to the Clinical and Laboratory Standards Institute (CLSI) guidelines either with or without the efflux pumps inhibitor, carbonyl cyanide 3-chlorophenylhydrazone (CCCP). Conventional polymerase chain reaction (PCR) was used to analyze the presence of pump genes.

Results: *Acinetobacter* isolates were identified as 2 species; *Acinetobacter baumannii* and *A. lwoffii*. Susceptibility testing showed high levels of resistance to amikacin in 27 isolates, including both *A. baumannii* and *A. lwoffii*, among which 20 *A. baumannii* isolates showed a 2- to 524288-fold reduction in amikacin MIC in the presence of CCCP, while no reduction occurred in amikacin MIC in resistant *A. lwoffii* isolates. The PCR results showed high frequencies of *adeB*, *abeM*, and *adeI* genes in *Acinetobacter* isolates yet the *adeE* gene was not found in any of the isolates.

Conclusions: The obtained results indicated the importance of efflux pumps in conferring resistance to amikacin in clinical isolates of *A. baumannii*, yet not in *A. lwoffii*.

Keywords: Amikacin, Antibiotic Resistance, CCCP, Efflux Pumps, *Acinetobacter baumannii*, *Acinetobacter lwoffii*

1. Background

The emergence and rapid spread of multidrug resistant (MDR) and pan-drug resistant (PDR) *Acinetobacter* strains causing nosocomial infections, are of global importance (1, 2). In general, the most important mechanisms of resistance in Gram negative pathogens are producing beta-lactamases and aminoglycoside modifying enzymes, reduction in the expression of outer membrane proteins, mutations in topoisomerases, and overexpression of efflux pumps. Unfortunately, combination of several resistance mechanisms leads to the development of MDR and even PDR strains (3). Efflux pumps exist in all living cells and protect them against toxic effects of organic chemical compounds. These pumps actively eject structurally

unrelated substrates, including antimicrobial of different classes, and cause the MDR phenotype.

Bacterial multi-drug resistance is often associated with overexpression of efflux pumps that reduces drug accumulation inside the bacterial cell, resulting in an increase in the minimum inhibitory concentration (MIC). Efflux pumps consist of 3 components, the inner membrane transporter, the outer membrane channel, and the periplasmic lipoprotein. Multidrug efflux pumps are generally encoded on the chromosome, and their overexpression is often associated with mutations in regulatory genes. However, drug-specific efflux pumps are encoded by mobile genetic elements and their acquisition is enough for conferring resistance (4). Multi-drug efflux systems are divided to 5 families (5), including ATP-Binding

cassette transporters (ABC), major facilitator superfamily (MFS), resistance-nodulation-division (RND), multidrug and toxic compound extrusion (MATE), and small multidrug resistance (SMR) based on structural homology, the number of subunits, the folding of the membrane, substrate specificity and energy source. Among all the efflux systems, the RND family is the most frequent in Gram negative bacteria.

Efflux-mediated resistance is important for 2 main reasons: In all metabolic processes, there is a high degree of specificity of enzyme activity and protein transport, while the efflux pumps identify a wide range of substrates with different chemical and structural characteristics and export them out of the bacterial cell (5). In addition, they allow bacteria to survive under stress conditions and increase the time of antibiotic exposure by delaying the death of bacteria, thus the chance of mutations, in order to earn higher levels of resistance (6, 7).

At first, antibiotic resistance associated with efflux pumps was limited to hydrophobic and amphiphilic compounds, such as quinolones, ampicillin, tetracycline, macrolides, beta-lactams, chloramphenicol, and rifampin (8). However, recently a few multidrug efflux systems have been reported as the active mechanisms of resistance to aminoglycosides in Gram-negative bacteria, such as (9) *Burkholderia pseudomallei*, *Pseudomonas aeruginosa* (10, 11), *Acinetobacter baumannii* (12), and *Escherichia coli* (13). Ade-ABC, an RND-type efflux pump, is reported to be associated with aminoglycoside resistance, as well as many other antibiotics (12). Overexpression of other RND-type efflux pumps, like AdeFGH and AdeIJK, also play a role in multidrug resistance in *A. baumannii*. A MATE family pump, AbeM, has also been reported to be involved in the multidrug resistance phenotype (14).

2. Objectives

The aim of this study was to further characterize the role of efflux pump in amikacin resistance in *Acinetobacter* isolates.

3. Methods

3.1. Ethics Statement

The ethics committee of Ferdowsi University of Mashhad approved the design and protocol of the study. The University ethics committee code number was IR.MUM.FUM.REC.1396.09. Names and characters, personal information and patients' illnesses and their medical information remained secret.

3.2. Specimen Collection and Identification

One hundred and thirty Gram negative bacilli were isolated from hospitalized patients at Shahid Kamyab and Ghaem hospitals in Mashhad, Iran from December 2014 to August 2015 (culture media were purchased from Merck, Germany). Bacterial identification was carried out by standard biochemical tests (Microgen GNA kit, United Kingdom) and *Acinetobacter* isolates were selected for further investigation.

3.3. Antimicrobial Susceptibility Tests

Susceptibilities to antimicrobial agents were determined for all *Acinetobacter* isolates using the disk diffusion (Kirby-Bauer) test according to clinical and laboratory standards institute (CLSI) protocol (15). Antibiotics used in disk diffusion tests, included ampicillin, amikacin, imipenem, ceftriaxone, ciprofloxacin, polymyxin B, carbenicillin, gentamicin, ceftazidime, cefotaxime, tobramycin, tetracyclines, piperacillin, amoxycylav, and amoxicillin (HiMedia, India).

3.4. Determination of Minimum Inhibitory Concentration

Amikacin MIC was determined in the range of 4 to 4096 $\mu\text{g}/\text{mL}$ for all amikacin-resistant *Acinetobacter* isolates. Determination of amikacin MIC was repeated in the presence of efflux pumps inhibitor, cyanide 3-chlorophenylhydrazone (CCCP) (Sigma Aldrich, USA), in order to investigate the role of efflux pumps in amikacin resistant isolates. To determine the appropriate concentration of CCCP in combination with amikacin (Sigma Aldrich, USA), an MIC determination of CCCP was also carried out and a concentration equal to 1/2 and 1/4 of the determined MIC was used as the non-inhibitory concentration. Determination of MIC values was carried out using the broth microdilution method in 96-well micro plates, according to CLSI standards (15).

3.5. Polymerase Chain Reaction

Distribution of efflux genes *adeB*, *adeE*, *adeI*, and *abeM* was investigated in all *Acinetobacter* isolates by the Polymerase Chain Reaction (PCR) directly from bacterial colonies using taq DNA polymerase master mix (Ampliqon, Denmark). The PCR conditions were as follows: Initial denaturation at 95°C for 5 minute, 30 cycles with denaturation at 94°C for 1 minute, 30 seconds annealing at 51°C for *adeB* and *abeM* genes, 45 seconds at 53.5°C and 51.5°C for *adeI* gene and *adeE* gene, respectively, extension at 72°C for 45 seconds, followed by final extension at 72°C for 10 minutes (Biorad, Germany). Primer pairs (Microgen, South Korea) for *adeB*, *adeI*, *abeM*, and *adeE* genes amplification are shown in Box 1.

Box 1. Primer Pairs for Genes Amplification

Primer Pairs for Each Gene
<i>adeB</i>
5'-TTAACGATAGCGTTGTAACC-3'
5'-TGAGCAGACAATGGAATAGT-3'
<i>adeI</i>
5'-ATCGCGCTTGTGGTTGTAG-3'
5'-AAGCACCAGCCGTTACTGAA-3'
<i>abeM</i>
5'-GTAGGTGTAGGCTTATGGA-3'
5'-GTACCGAAGTGACTGAAAT-3'
<i>adeE</i>
5'-GAGCTGAGGATTCTCTATGT-3'
5'-AGTGTGCTCACCATATAGTC-3'

4. Results

4.1. Identification of Bacterial Isolates

Out of 130 isolates, a total number of 46 *Acinetobacter* isolates were identified, 33 isolates (71.7%) identified as *A. baumannii* and 13 isolates (28.3%) as *A. lwoffii*. *Acinetobacter* samples were isolated from throat (6 isolates), lungs (3 isolates), bronchi (4 isolates), trachea (3 isolates), mucus (1 isolate), general secretions (11 isolates), ascites (2 isolates), bone (1 isolate), urinary (2 isolates), and wound (13 isolates) sources from hospitalized patients in internal medicine (4 isolates), surgery (5 isolates), intensive care unit (23 isolates), and orthopedic (14 isolates) wards of Ghaem (14 isolates) and Shahid Kamyab (32 isolates) hospitals.

4.2. Antibiotic Susceptibility Tests

The pattern of antibiotic resistance in *Acinetobacter* isolates is shown in Table 1. All the isolates were multidrug resistant and showed resistance to most tested antibiotics. The highest degree of resistance (100%) was observed against amoxicillin and tetracycline. The least degree of resistance was observed against polymyxin B (10.86%) and amikacin (58.69%). Out of 46 *Acinetobacter* isolates, 27 isolates were resistant to amikacin.

4.3. Determination of Minimum Inhibitory Concentration

Determination of CCCP MIC was conducted for each of the amikacin-resistant *Acinetobacter* isolates. It ranged from 1.56 to 50 µg/mL among 27 *Acinetobacter* isolates, which was 25 to 50 µg/mL in most cases (20 isolates). Amikacin MIC determination in each of the 27 amikacin resistant isolates was also carried out alone and in the presence of CCCP. In all amikacin-resistant bacteria, a high level

Table 1. Percentage of Resistance and Sensitivity of *Acinetobacter* Isolates to Different Antibiotics

Variables	Resistance	Sensitivity
AK	58.69	41.31
IPM	82.7	17.3
PB	10.86	89.14
CB	89.13	10.87
CFM	89.13	10.87
CIP	86.95	10.05
GEN	91.3	8.7
CAZ	89.13	10.87
CTX	86.95	10.05
TOB	93.47	6.53
TE	100	0
CTR	93.47	6.53
PI	95.65	4.35
AMX	100	0
AMC	93.47	6.53
AMP	95.65	4.35

Abbreviations: AK, Amikacin; AMC, Amoxyclyl; AMP, Ampicillin; AMX, Amoxicillin; CAZ, Ceftazidime; CB, Carbenicillin; CFM, Cefixime; CIP, Ciprofloxacin; CTR, Ceftriaxone; CTX, Cefotaxime; GEN, Gentamicin; IPM, Imipenem; PB, Polymyxin B; PI, Piperacillin; TE, Tetracycline; TOB, Tobramycin.

of resistance to amikacin (1024 to 4096 µg/mL) was observed.

Out of 27 amikacin-resistant *Acinetobacter* isolates, 23 isolates (85.2% of resistant isolates) were identified as *A. baumannii* and 4 isolates (14.8%) were identified as *A. lwoffii*, among which 20 *A. baumannii* isolates, yet no *A. lwoffii* isolates, showed a 2- to 524288-fold reduction in amikacin MIC in the presence of CCCP, indicating the involvement of efflux pumps in resistance to amikacin. Table 2 shows amikacin MIC values of resistant isolates in the presence and absence of 2 different CCCP concentrations.

4.4. Polymerase Chain Reaction

The *adeB*, *abeM*, and *adeI* genes were observed in 36 (78.26%), 37 (80.43%), and 36 (78.26%) *Acinetobacter* isolates, respectively, while *adeE* gene was not found in any of the isolates (0%). Figure 1 shows the PCR amplification of the genes in some *Acinetobacter* isolates. Table 3 shows the genetic patterns observed in *Acinetobacter* isolates.

Among 20 *A. baumannii* isolates, which showed a decreased MIC in presence of CCCP, the *AdeI* gene was found in 19 isolates and *adeB* and *abeM* genes were found in all isolates. Among *A. lwoffii* isolates, 3 isolates contained all

Table 2. Amikacin MIC Values of Resistant Isolates in the Presence and Absence of two Different Concentrations of CCCP^a

Number	Species	MIC of Amikacin, $\mu\text{g/mL}$	Amikacin MIC in Presence of CCCP (1/2)	Reduction in MIC of Amikacin	Amikacin MIC in Presence of CCCP (1/4)	Reduction in MIC of Amikacin
1 ^b	<i>A. baumannii</i>	1024	128	1/8	512	1/2
2	<i>A. lwoffii</i>	2048	2048	No change	2048	No change
3	<i>A. baumannii</i>	1024	1024	No change	1024	No change
4 ^b	<i>A. baumannii</i>	4096	1024	1/4	4096	No change
5 ^b	<i>A. baumannii</i>	4096	2048	1/2	2048	1/2
6	<i>A. baumannii</i>	4096	4096	No change	4096	No change
7 ^b	<i>A. baumannii</i>	4096	1024	1/4	2048	1/2
8 ^b	<i>A. baumannii</i>	2048	1024	1/2	2048	No change
9	<i>A. lwoffii</i>	4096	4096	No change	4096	No change
11 ^b	<i>A. baumannii</i>	4096	512	1/8	4096	No change
12 ^b	<i>A. baumannii</i>	4096	512	1/8	512	1/8
15 ^b	<i>A. baumannii</i>	4096	512	1/8	1024	1/4
17 ^c	<i>A. baumannii</i>	4096	64	1/64	256	1/64
18 ^b	<i>A. baumannii</i>	4096	2048	1/2	4096	No change
19 ^d	<i>A. baumannii</i>	2048	0.0039	1/524288	4	1/512
24 ^d	<i>A. baumannii</i>	4096	4	1/1024	2048	1/1
25 ^d	<i>A. baumannii</i>	4096	8	1/512	8	1/512
27 ^b	<i>A. baumannii</i>	4096	2048	1/2	4096	No change
28 ^d	<i>A. baumannii</i>	4096	4	1/1024	4	1/1024
29	<i>A. baumannii</i>	2048	2048	No change	2048	No change
30 ^d	<i>A. baumannii</i>	4096	8	1/512	2048	1/2
31 ^c	<i>A. baumannii</i>	4096	256	1/16	256	1/16
37 ^c	<i>A. baumannii</i>	4096	128	1/32	4096	No change
42 ^c	<i>A. baumannii</i>	4096	32	1/128	256	1/16
43	<i>A. lwoffii</i>	4096	4096	No change	4096	No change
44 ^c	<i>A. baumannii</i>	4096	256	1/16	2048	1/2
45	<i>A. lwoffii</i>	4096	4096	No change	4096	No change

^aCCCP (1/2), a concentration of CCCP equals to one half of its MIC determined for the specific isolate; CCCP (1/4), a concentration of CCCP equals to a quarter of its MIC determined for the specific isolate.

^bIsolates with mild reduction in amikacin MIC in the presence of CCCP.

^cIsolates with high levels of reduction in amikacin MIC in the presence of CCCP.

^dIsolates with extreme levels of reduction in amikacin MIC in the presence of CCCP.


3 genes at the same time, 7 isolates contained none of the mentioned genes, and the rest contained 1 of the *adeB*, *abeM* or *adel* genes.

5. Discussion

The aim of present study was to investigate the role of efflux pumps in amikacin resistance in *Acinetobacter* isolates. The results of the identification of *Acinetobacter* species confirmed both the importance of *A. baumannii*

in nosocomial infections, which is the center of attention in many researches all around the world (16, 17), and also highlighted the significance of *A. lwoffii* in the same topic, which was neglected by the studies of resistance patterns and mechanisms. In a study by Constantiniu et al. in 2004 on 24 isolates of *Acinetobacter*, 12 environmental and 12 clinical samples, 3 clinical isolates (25%) and 4 environmental isolates (33.33%) were identified as *A. lwoffii* and the rest were identified as *A. baumannii* species (18). In the present study, *A. lwoffii* isolates showed almost the same propor-

Figure 1. Polymerase Chain Reaction Amplification of Genes in *Acinetobacter* Isolates



A, 100 base pair (bp) DNA Ladder, 1 - 13 Products of PCR, Lower bands show the amplification of *adeB* gene (541 bp) and upper bands show the amplification of *abeM* gene (703bp). B, 100 bp DNA Ladder, 1 - 13 Products of PCR of *adel* gene (541 bp). C, 100 bp DNA Ladder, amplification of *adeE* gene did not happen (expected size: 504 bp).

Table 3. Frequencies of Genetic Patterns of *adeB*, *abeM*, *adel* and *adeE* Genes in *Acinetobacter* Isolates

Genotype Pattern	Frequency	Relative Frequency,%
<i>adeB</i> +/ <i>adel</i> +/ <i>abeM</i> +	34	73.91
<i>abeM</i> , <i>adeB</i>	1	2.17
<i>adel</i> +/ <i>abeM</i>	1	2.17
<i>adel</i>	1	2.17
<i>adeB</i>	1	2.17
<i>abeM</i>	1	2.17
None	7	15.21

tion (28.3%) among clinical samples.

In the presence of CCCP, a reduction of 2 to 524288 folds in amikacin MIC was observed in 74.07% of resistant isolates. The decline rate of 8 and 2 times in amikacin MIC in *Acinetobacter* was reported by Magnet et al. (12) and Nikasa et al. (19) respectively. Ardebili et al. reported 2 to 64 folds of reduction in ciprofloxacin MIC in 86.1% of *Acinetobacter* isolates (20). In this study, among 20 *A. baumannii* isolates, which showed a reduction in amikacin MIC in the presence of CCCP, 10 isolates (50%) showed a mild reduction (2 to 8 folds), 5 isolates (25%) showed high levels of reduction (16 to 128 folds), and extreme reduction (256 to 524288 fold) was observed in 5 isolates (25%). According to CLSI standards (15), amikacin MIC value of less or equal to 16 µg/mL (16 µg/mL ≥ MIC) in *Acinetobacter* species is considered as

the range of sensitivity. If it is assumed that the conversion from resistant to a sensitive isolate after inhibiting efflux pumps activity, indicates the role of efflux pumps as the single mechanism responsible for the resistance, then the 5 *A. baumannii* isolates of this study, Ac19, Ac24, Ac25, Ac28 and Ac30, would be classified in such a group. These isolates included 18.52% of all amikacin resistant isolates.

According to a study by Chau et al., *adeE* pump belonging to the RND family had the ability to export antibiotics, including aminoglycosides (21). The *AdeE* gene is often observed in *Acinetobacter GDG3* and does not coexist with *adeABC* efflux pump, according to the study by Lin et al. (22). The results of the present study on the *adeE* gene showed no evidence of this gene in *A. baumannii* and *A. lwoffii*. Magnet et al. (12) reported *adeABC* pump activity responsible for the resistance to aminoglycosides in *Acinetobacter baumannii* BM4454. Bratu et al. also attributed the resistance to aminoglycosides and fluoroquinolones to the presence of this pump (23). Japoni Nejad et al. (24) as well as Gholami et al. (25) reported the presence of *adeB* gene in all of their studied *A. baumannii* isolates, which is very close to the results of the present study (97%).

AbeM is an efflux pump belonging to the MATE family, which is involved in resistance to norfloxacin, ofloxacin, ciprofloxacin, gentamicin, doxorubicin, and triclosan, according to the research conducted by Su et al. (14). The presence of *abeM* gene in all 20 isolates with efflux-mediated resistance to amikacin in this study could be due to its contribution to amikacin resistance. Overexpression of *AdeJJK* pump could cause resistance to beta-lactams, chloramphenicol, tetracycline, erythromycin, fluoroquinolones, fusidic acid, novobiocin, and trimethoprim (26, 27). In a study by Yoon et al. (28), this gene was found in all clinical isolates without any increased expression. The PCR results in a study done by Kor et al. showed that 67.4% of *A. baumannii* isolates contained the *adeA* and *adeI* genes (29). However, in the present study, the *adeB* gene of *adeABC* pump coexists with *adeI* in 93.9% of *A. baumannii* isolates. It appears that the activity of these pumps, particularly in cooperation with each other could contribute to the resistance to amikacin in *A. baumannii*.

6. Conclusions

Based on the results of this study, very high contribution of efflux pumps to amikacin resistance in *A. baumannii* isolates indicates the great importance of this mechanism in antibiotic resistance. It could rapidly spread among *A. baumannii* isolates, which is alarming and shows an urgent need for further research in order to design efflux pump inhibitors capable of simultaneous use with antibiotics in treatment.

Acknowledgments

The authors thank the staff of the microbiology laboratories of Ghaem and Shahid Kamyab hospitals of Mashhad for their help with collecting the clinical isolates.

Footnotes

Authors' Contribution: Study concept and design, Mohammad Reza Sharifmoghdam; acquisition of data, Kiarash Ghazvini and Asghar Mafinezhad; analysis and interpretation of data, Maryam Abbasi Shaye and Ghazale Amiri; drafting of the manuscript, Maryam Abbasi Shaye; critical revision of the manuscript for important intellectual content, Mohammad Reza Sharifmoghdam; statistical analysis, Maryam Abbasi Shaye; administrative, technical, and material support, Mohammad Reza Sharifmoghdam, and Masoumeh Bahreini; study supervision, Mohammad Reza Sharifmoghdam.

Financial Disclosure: All authors declare that they had no conflict of interest.

Funding/Support: This study was funded by Ferdowsi University of Mashhad.

References

1. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegmang-Igra Y, Carmeli Y. Multidrug-resistant *Acinetobacter baumannii*. *Emerg Infect Dis*. 2005;11(1):22-9. doi: [10.3201/eid1101.040001](https://doi.org/10.3201/eid1101.040001). [PubMed: [15705318](https://pubmed.ncbi.nlm.nih.gov/15705318/)].
2. Jain R, Danziger LH. Multidrug-resistant *Acinetobacter* infections: an emerging challenge to clinicians. *Ann Pharmacother*. 2004;38(9):1449-59. doi: [10.1345/aph.1D592](https://doi.org/10.1345/aph.1D592). [PubMed: [15280512](https://pubmed.ncbi.nlm.nih.gov/15280512/)].
3. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa*. *Clin Infect Dis*. 2006;43 Suppl 2:S49-56. doi: [10.1086/504477](https://doi.org/10.1086/504477). [PubMed: [16894515](https://pubmed.ncbi.nlm.nih.gov/16894515/)].
4. Lin MF, Lin YY, Tu CC, Lan CY. Distribution of different efflux pump genes in clinical isolates of multidrug-resistant *Acinetobacter baumannii* and their correlation with antimicrobial resistance. *J Microbiol Immunol Infect*. 2017;50(2):224-31. doi: [10.1016/j.jmii.2015.04.004](https://doi.org/10.1016/j.jmii.2015.04.004). [PubMed: [26055688](https://pubmed.ncbi.nlm.nih.gov/26055688/)].
5. Poole K. Outer membranes and efflux: the path to multidrug resistance in Gram-negative bacteria. *Curr Pharm Biotechnol*. 2002;3(2):77-98. doi: [10.2174/1389201023378454](https://doi.org/10.2174/1389201023378454). [PubMed: [12022261](https://pubmed.ncbi.nlm.nih.gov/12022261/)].
6. Lomovskaya O, Watkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. *J Mol Microbiol Biotechnol*. 2001;3(2):225-36. [PubMed: [11321578](https://pubmed.ncbi.nlm.nih.gov/11321578/)].
7. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic—a vision for applied use. *Biochem Pharmacol*. 2006;71(7):910-8. doi: [10.1016/j.bcp.2005.12.008](https://doi.org/10.1016/j.bcp.2005.12.008). [PubMed: [16427026](https://pubmed.ncbi.nlm.nih.gov/16427026/)].
8. Nikaido H. Antibiotic resistance caused by gram-negative multidrug efflux pumps. *Clin Infect Dis*. 1998;27 Suppl 1:S32-41. doi: [10.1086/514920](https://doi.org/10.1086/514920). [PubMed: [9710669](https://pubmed.ncbi.nlm.nih.gov/9710669/)].
9. Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE. Efflux-mediated aminoglycoside and macrolide resistance in *Burkholderia pseudomallei*. *Antimicrob Agents Chemother*. 1999;43(3):465-70. [PubMed: [10049252](https://pubmed.ncbi.nlm.nih.gov/10049252/)].

10. Aires JR, Kohler T, Nikaido H, Plesiat P. Involvement of an active efflux system in the natural resistance of *Pseudomonas aeruginosa* to aminoglycosides. *Antimicrob Agents Chemother.* 1999;**43**(11):2624-8. [PubMed: [10543738](#)].
11. Westbrock-Wadman S, Sherman DR, Hickey MJ, Coulter SN, Zhu YQ, Warrener P, et al. Characterization of a *Pseudomonas aeruginosa* efflux pump contributing to aminoglycoside impermeability. *Antimicrob Agents Chemother.* 1999;**43**(12):2975-83. [PubMed: [10582892](#)].
12. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in *Acinetobacter baumannii* strain BM4454. *Antimicrob Agents Chemother.* 2001;**45**(12):3375-80. doi: [10.1128/AAC.45.12.3375-3380.2001](#). [PubMed: [11709311](#)].
13. Rosenberg EY, Ma D, Nikaido H. AcrD of *Escherichia coli* is an aminoglycoside efflux pump. *J Bacteriol.* 2000;**182**(6):1754-6. [PubMed: [10692383](#)].
14. Su XZ, Chen J, Mizushima T, Kuroda T, Tsuchiya T. AbeM, an H⁺-coupled *Acinetobacter baumannii* multidrug efflux pump belonging to the MATE family of transporters. *Antimicrob Agents Chemother.* 2005;**49**(10):4362-4. doi: [10.1128/AAC.49.10.4362-4364.2005](#). [PubMed: [16189122](#)].
15. Clinical and Laboratory Standards Institute . *Performance Standards for Antimicrobial Susceptibility Testing*. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2014.
16. Neonakis I, Gikas A, Scoulica E, Manios A, Georgiladakis A, Tselenitis Y. Evolution of aminoglycoside resistance phenotypes of four Gram-negative bacteria: an 8-year survey in a University Hospital in Greece. *Int J Antimicrob Agents.* 2003;**22**(5):526-31. doi: [10.1016/S0924-8579\(03\)00152-3](#). [PubMed: [14602373](#)].
17. Fihman V, Lartigue MF, Jacquier H, Meunier F, Schnepf N, Raskine L, et al. Appearance of aac(6)-Ib-cr gene among extended-spectrum beta-lactamase-producing Enterobacteriaceae in a French hospital. *J Infect.* 2008;**56**(6):454-9. doi: [10.1016/j.jinf.2008.03.010](#). [PubMed: [18440645](#)].
18. Constantiniu S, Romaniuc A, Iancu LS, Filimon R, Tarași, I . Cultural and biochemical characteristics of *Acinetobacter* spp. strains isolated from hospital units. *J Prevent Med.* 2004;**12**(3-4):35-42.
19. Nikasa P, Abdi-Ali A, Rahmani-Badi A, Al-Hamad A. In vitro evaluation of proton motive force-dependent efflux pumps among multidrug resistant *Acinetobacter baumannii* isolated from patients at Tehran Hospitals. *Jundishapur J Microbiol.* 2013;**6**(7). doi: [10.5812/jjm.6792](#).
20. Ardebili A, Lari AR, Talebi M. Correlation of ciprofloxacin resistance with the AdeABC efflux system in *Acinetobacter baumannii* clinical isolates. *Ann Lab Med.* 2014;**34**(6):433-8. doi: [10.3343/alm.2014.34.6.433](#). [PubMed: [25368818](#)].
21. Chau SL, Chu YW, Houang ET. Novel resistance-nodulation-cell division efflux system AdeDE in *Acinetobacter* genomic DNA group 3. *Antimicrob Agents Chemother.* 2004;**48**(10):4054-5. doi: [10.1128/AAC.48.10.4054-4055.2004](#). [PubMed: [15388479](#)].
22. Lin L, Ling BD, Li XZ. Distribution of the multidrug efflux pump genes, adeABC, adeDE and adeIJK, and class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of *Acinetobacter baumannii*-*Acinetobacter calcoaceticus* complex. *Int J Antimicrob Agents.* 2009;**33**(1):27-32. doi: [10.1016/j.ijantimicag.2008.06.027](#). [PubMed: [18790612](#)].
23. Bratu S, Landman D, Martin DA, Georgescu C, Quale J. Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of *Acinetobacter baumannii* endemic to New York City. *Antimicrob Agents Chemother.* 2008;**52**(9):2999-3005. doi: [10.1128/AAC.01684-07](#). [PubMed: [18591275](#)].
24. Japoni Nejad AR, Sofian M, Ghaznavi-Rad E. Molecular detection of AdeABC efflux pump genes in clinical isolates of *Acinetobacter baumannii* and their contribution in imipenem resistance [In Persian]. *Iran South Med J.* 2014;**17**(5):815-23.
25. Gholami M, Hashemi A, Hakemi-Vala M, Goudarzi H, Hallajzadeh M. Efflux Pump Inhibitor Phenylalanine-Arginine Beta-Naphthylamide Effect on the Minimum Inhibitory Concentration of Imipenem in *Acinetobacter baumannii* Strains Isolated From Hospitalized Patients in Shahid Motahari Burn Hospital, Tehran, Iran. *Jundishapur J Microbiol.* 2015;**8**(10). e19048. doi: [10.5812/jjm.19048](#). [PubMed: [26568800](#)].
26. Damier-Piolle L, Magnet S, Bremont S, Lambert T, Courvalin P. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2008;**52**(2):557-62. doi: [10.1128/AAC.00732-07](#). [PubMed: [18086852](#)].
27. Coyne S, Courvalin P, Perichon B. Efflux-mediated antibiotic resistance in *Acinetobacter* spp. *Antimicrob Agents Chemother.* 2011;**55**(3):947-53. doi: [10.1128/AAC.01388-10](#). [PubMed: [21173183](#)].
28. Yoon EJ, Courvalin P, Grillot-Courvalin C. RND-type efflux pumps in multidrug-resistant clinical isolates of *Acinetobacter baumannii*: major role for AdeABC overexpression and AdeRS mutations. *Antimicrob Agents Chemother.* 2013;**57**(7):2989-95. doi: [10.1128/AAC.02556-12](#). [PubMed: [23587960](#)].
29. Kor SB, Chew CH. Distribution of the multidrug efflux pump genes adeA, adeI, adeJ, adeY and integrons in clinical isolates of *Acinetobacter baumannii* from Malaysian hospitals. *Biomed Res.* 2014;**25**(2).